Buprenorphine for the treatment of the neonatal abstinence syndrome

New England Journal of Medicine

Volumn 376, Issue 24, 2017, Pages 2341-2348

  Kraft, Walter K ^a   Adeniyi Jones, Susan C ^a,b   Chervoneva, Inna ^a   Greenspan, Jay S ^b   Abatemarco, Diane ^a   Kaltenbach, Karol ^a   Ehrlich, Michelle E ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; MORPHINE; OPIATE; PHENOBARBITAL; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEONATAL ABSTINENCE SYNDROME; NEWBORN; NEWBORN CARE; PIERRE ROBIN SYNDROME; PRENATAL EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; OPIATE SUBSTITUTION TREATMENT; ORAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BUPRENORPHINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT, NEWBORN; LENGTH OF STAY; MALE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PHENOBARBITAL;

EID: 85020487849     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1614835     Document Type: Article

References (18)

1. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics 2012; 129(2): e540-e560.
2. Holmes AV, Atwood EC, Whalen B, et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics 2016; 137(6): e20152929.
3. Short VL, Gannon M, Abatemarco DJ. The association between breastfeeding and length of hospital stay among infants diagnosed with neonatal abstinence syndrome: A population-based study of in-hospital births. Breastfeed Med 2016; 11: 343-9.
4. Patrick SW, Schumacher RE, Horbar JD, et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016; 137(5): e20153835.
5. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010; CD002059.
6. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2017; 2: CD002025.
7. Ng CM, Dombrowsky E, Lin H, et al. Population pharmacokinetic model of sublingual buprenorphine in neonatal abstinence syndrome. Pharmacotherapy 2015; 35: 670-80.
8. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: A randomized trial. Pediatrics 2008; 122(3): e601-e607.
9. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011; 106: 574-80.
10. Kaltenbach K, Jones HE. Neonatal abstinence syndrome: presentation and treatment considerations. J Addict Med 2016; 10: 217-23.
11. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of buprenorphine for sublingual use in neonates. J Pediatr Pharmacol Ther 2011; 16: 281-4.
12. Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. J Addict Med 2013; 7: 113-5.
13. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 351-61.
14. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997; 53: 983-97.
15. Barrett DA, Simpson J, Rutter N, Kurihara-Bergstrom T, Shaw PN, Davis SS. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol 1993; 36: 215-9.
16. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35: 344-6.
17. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199(4): 396.e1-7.
18. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118: 933-7.